Global Hemoglobinopathies Market Projected to Reach USD 13,465.2 Million by 2026

19-May-2020 | Facts and Factors

[185+ Pages Report] According to the report published by Facts Factors, the global Hemoglobinopathies market size was worth around USD 5,423.5 million in 2019 and is predicted to grow to around USD 13,465.2 million by 2026 with a compound annual growth rate (CAGR) of roughly 10.34% between 2020 and 2026. The report analyzes the global hemoglobinopathies market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the hemoglobinopathies market.

Hemoglobinopathies are caused by defects in the genes and by anemia. Default hemoglobin formation is observed in three conditions, such as hemoglobin molecule structural defects, reduced production of one of the two hemoglobin molecule subunits, and abnormal interactions of otherwise safe subunits. There can be serious or mild illnesses. Genetic diagnosis, genetic and blood testing, electrophoresis of alkaline and acid gel, hemoglobin electrophoresis, genetic prenatal testing, and chromatography exchange of ions HbA2 are the most common tools/tests for diagnosis of hemoglobinopathy and thalassemia.

Improved R&D investments are projected to contribute to demand development for new therapies. The National Heart, Lung, and Blood Institute (NHLBI), part of the National Health Institutes (NIH), is funding SCD research programs to find new methods of identifying and managing the disease and enhancing patient outcomes. New techniques are being developed using advances in gene-editing technology to modify or delete the faulty sickle cell disease gene and carry the restored gene back to the patients. Through support for sickle cell disease prevention and care through legislation such as the Sickle Cell Disease Research, Surveillance, Prevention, and Care Act, 2018 is also likely to lead to better management of the situation.

Browse the full “Hemoglobinopathies Market by Indication (Sickle cell disease, Alpha Thalassemia, Beta Thalassemia and Others), Therapy (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, and Others), Diagnosis (Blood testing, Genetic testing, Pre-implantation Genetic Diagnosis (PGD) and Other), and end-user (Hospitals, Diagnostic Laboratories, Clinics, and Other End-user): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" https://www.fnfresearch.com/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

The Hemoglobinopathies market is segmented into indication, therapy, diagnosis, end-user and region segment. The indication segment is segmented into sickle cell disease, alpha-thalassemia, beta-thalassemia, and others. The therapy segment is divided into iron chelation therapy, blood transfusion, bone marrow transplant, and others. In 2018, blood transfusion therapy held the largest market share. Rising policy measures to increase the number of blood donors are a high impact making engine for the demand for hemoglobinopathies. The Diagnosis segment is bifurcated into blood testing, genetic testing, pre-implantation genetic diagnosis (PGD), and Others. In 2018, blood testing dominated the diagnosis segment in terms of revenue. The fact that blood testing is extensively used as the tool of first-line screening is a major contributor to its large market share. Due to its efficacy in precise diagnosis and monitoring, genetic testing for sickle cell disease diagnosis is projected to be the fastest-growing segment over the forecast timespan. The end-user segment is segmented into hospitals, diagnostic laboratories, clinics, and other end-user.

Geography-wise, the market is segmented into North America, Europe, Assia Pacific, Latin America, and the Middle East and Africa. Owing to rising R&D investments by key players, a better reimbursement scenario, and the availability of high-quality healthcare services, North America led the overall market in revenue in 2018. The Asia Pacific is expected to experience the fastest growth over the projected period. The launch of indigenously made, low-cost diagnostic kits for thalassemia and sickle cell disease coupled with increasing patient awareness is expected to provide lucrative growth opportunities for manufacturers in the near future.

Report Scope

Top key players operating in the market are Alnylam Pharmaceuticals, bluebird bio Inc., Celgene Corporation, Emmaus Life Sciences Inc., Gamida Cell, Global Blood Therapeutics, Prolong Pharmaceuticals, Sangamo, Therapeutics Inc., Sanofi amongst others.

This report segments the Global Hemoglobinopathies Market as follows:

By Indication Segment Analysis

• Sickle cell disease
• Alpha Thalassemia
• Beta Thalassemia
• Others

By Therapy Segment Analysis

• Blood Transfusion
• Iron Chelation Therapy
• Bone Marrow Transplant
• Others

By Diagnosis Segment Analysis

• Blood testing
• Genetic testing
• Pre-implantation Genetic Diagnosis (PGD)
• Other

By End-user Segment Analysis

• Hospitals
• Diagnostic laboratories
• Clinics
• Other End-use

Global HemoglobinopathiesMarket: Regional Segmentation Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • The UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa

Rest of Middle East & Africa

About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:

Facts & Factors
A - 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com